These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24969610)

  • 1. [New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)].
    Gallwitz B; Nitschmann S
    Internist (Berl); 2014 Jul; 55(7):859-62. PubMed ID: 24969610
    [No Abstract]   [Full Text] [Related]  

  • 2. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Standl E
    N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
    Greenhill C
    Nat Rev Endocrinol; 2013 Nov; 9(11):625. PubMed ID: 24061081
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes: Cardiovascular safety of 'gliptin' therapy.
    Lim GB
    Nat Rev Cardiol; 2013 Nov; 10(11):616. PubMed ID: 24042219
    [No Abstract]   [Full Text] [Related]  

  • 5. Gliptins - do they increase cardiovascular risk or benefit?
    Doggrell SA; Dimmitt SB
    Expert Opin Drug Saf; 2014 May; 13(5):675-80. PubMed ID: 24684173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin, alogliptin, and cardiovascular outcomes.
    White WB; Zannad F
    N Engl J Med; 2014 Jan; 370(5):484. PubMed ID: 24482824
    [No Abstract]   [Full Text] [Related]  

  • 7. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P
    Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
    Schernthaner G; Cahn A; Raz I
    Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
    [No Abstract]   [Full Text] [Related]  

  • 9. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
    Špinar J; Špinarová L; Vítovec J
    Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Scirica BM; Braunwald E; Bhatt DL
    N Engl J Med; 2014 Jan; 370(5):483-4. PubMed ID: 24476444
    [No Abstract]   [Full Text] [Related]  

  • 11. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
    White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
    N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
    N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Derosa G; Maffioli P
    N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
    [No Abstract]   [Full Text] [Related]  

  • 15. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Simó R; Hernández C
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
    [No Abstract]   [Full Text] [Related]  

  • 16. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
    Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
    Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oral hypoglycaemics fail to show cardiovascular benefits.
    Cohen D
    BMJ; 2013 Sep; 347():f5458. PubMed ID: 24014343
    [No Abstract]   [Full Text] [Related]  

  • 18. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Price DL; Chen R; Udell J; Raz I
    Am Heart J; 2011 Nov; 162(5):818-825.e6. PubMed ID: 22093196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
    Hirshberg B; Katz A
    Curr Diab Rep; 2015 Nov; 15(11):87. PubMed ID: 26370698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
    White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
    Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.